Business Context and Reporting Period
This Form 10-Q covers the fiscal quarter and six months ended March 31, 2003, for AmerisourceBergen Corporation (now Cencora, Inc.). The Company is a leading national wholesale distributor of pharmaceutical products and related healthcare services, operating through two primary segments: Pharmaceutical Distribution and PharMerica. The reporting period reflects the ongoing integration of the 2001 merger between AmeriSource Health Corporation and Bergen Brunswig Corporation.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2003 | Six Months Ended Mar 31, 2003 |
|---|---|---|
| Operating Revenue | $11,213,959 | $22,320,864 |
| Total Revenue (incl. bulk deliveries) | $12,162,541 | $24,597,074 |
| Gross Profit | $581,189 | $1,102,614 |
| Operating Income | $236,552 | $424,407 |
| Net Income | $116,414 | $209,153 |
| Diluted EPS | $1.03 | $1.87 |
| Cash and Equivalents (End of Period) | $225,956 | $225,956 |
| Total Debt (Current + Long-term) | $2,061,738 | $2,061,738 |
| Operating Cash Flow (Six Months) | $(615,271) | $(615,271) |
Margins (Six Months Ended Mar 31, 2003):
- Gross Profit Margin: 4.94% of operating revenue
- Operating Income Margin: 1.90% of operating revenue
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 13% for the quarter and 14% for the six-month period compared to the prior year, driven primarily by the Pharmaceutical Distribution segment.
- Profitability: Net income rose 27% for the quarter and 31% for the six-month period. Operating income increased 24% year-over-year for both periods.
- Cash Flow: Operating activities used $615.3 million in cash for the six months ended March 31, 2003, a significant shift from the $225.5 million generated in the prior-year period. This was primarily due to a $1.45 billion increase in merchandise inventories to support revenue growth and capture buy-side opportunities.
- Acquisitions: The Company acquired US Bioservices Corporation (Jan 2003) and Bridge Medical, Inc. (Jan 2003), adding specialty pharmaceutical and supply chain software capabilities.
Guidance, Outlook, and Risks
- Revenue Outlook: Management expects Pharmaceutical Distribution revenue growth to decline from the first-half rate of 14% to approximately 11%–12% for the second half of fiscal 2003, citing patent expirations and slower new drug introductions.
- Margin Pressures: Downward pressure on sell-side gross profit margins is expected to continue due to competitive pricing and customer mix shifts toward large institutional accounts.
- Integration Synergies: The Company aims to achieve approximately $150 million in annual synergies by the end of fiscal 2004 through facility consolidation (targeting a network of 30 facilities) and administrative efficiencies.
- Debt Management: In November 2002, the Company issued $300 million in 7.25% senior notes. Proceeds were used to repay term loans and senior notes. Subsequent to the period end, the Company redeemed PharMerica's 8.375% senior subordinated notes.
- Risks: Key risks include interest rate fluctuations (significant exposure to variable-rate debt), regulatory changes, customer insolvencies, and the success of merger integration efforts.
Investor Verification Checklist
- Inventory Build: Verify the sustainability of the $1.45 billion inventory increase and its impact on future working capital requirements.
- Margin Trends: Monitor the gross profit margin compression in the Pharmaceutical Distribution segment against the backdrop of competitive pricing.
- Debt Covenants: Review compliance with leverage and fixed charge coverage ratios under the Senior Credit Agreement, especially given the high debt load ($2.06 billion).
- Acquisition Integration: Assess the realization of synergies from the US Bioservices and Bridge Medical acquisitions and the ongoing facility consolidation plan.
- Seasonality: Confirm the expectation that operating cash flow will reverse in the second half of the fiscal year to offset the first-half cash usage.